Yungpo Wang, MD
Nephrology · Baldwin Park, CANPI 1639228919
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (32.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 70.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $288 and has fallen 51.3% since, to $140 in 2023. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 12 payments — averaging $51.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$435
- GSK$140
- Pfizer$38
Across 4 payments — averaging $60,364 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$241K
What the payments were for
- Consulting fees$14023%
- Speaking & faculty fees$20033%
- Food & beverage$19832%
- Education$7512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 7 | $435 |
| GSK | 2 | $140 |
| Pfizer | 3 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$321
How this compares
$613 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $49,345 |
| Sevelamer Carbonate | 70 | $18,344 |
| Sodium Polystyrene Sulfonate | 38 | $4,704 |
| Calcium Acetate | 38 | $4,339 |
| Calcitriol | 237 | $3,926 |
| Hydralazine Hcl | 117 | $2,603 |
| Furosemide | 171 | $2,140 |
| Amlodipine Besylate | 170 | $2,071 |
| Losartan Potassium | 155 | $1,946 |
| Nifedipine ErNifedipine | 37 | $1,669 |
| Terazosin Hcl | 33 | $1,405 |
| Potassium Chloride | 24 | $962 |
| Lisinopril | 59 | $832 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 39 | $659 |
| Bisoprolol Fumarate | 29 | $625 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Baldwin Park
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.